Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Cost-effectiveness of testing for breast cancer susceptibility genes.

Holland ML, Huston A, Noyes K.

Value Health. 2009 Mar-Apr;12(2):207-16. doi: 10.1111/j.1524-4733.2008.00418.x. Epub 2008 Jul 18.

2.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
3.

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C.

JAMA. 1997 Mar 26;277(12):997-1003. Review.

PMID:
9091675
4.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):362-79. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144895
5.

Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.

Wainberg S, Husted J.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1989-95. Review.

6.

Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.

Roukos DH, Briasoulis E.

Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.

PMID:
17898808
7.

Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Salhab M, Bismohun S, Mokbel K.

BMC Womens Health. 2010 Oct 20;10:28. doi: 10.1186/1472-6874-10-28. Review.

8.

Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.

Kuschel B, Lux MP, Goecke TO, Beckmann MW.

Eur J Cancer Prev. 2000 Jun;9(3):139-50. Review.

PMID:
10954253
9.

Strategies for ovarian cancer prevention.

Dann RB, Kelley JL, Zorn KK.

Obstet Gynecol Clin North Am. 2007 Dec;34(4):667-86, viii. Review.

PMID:
18061863
10.
11.

Clinical management of women with genomic BRCA1 and BRCA2 mutations.

Chang J, Elledge RM.

Breast Cancer Res Treat. 2001 Sep;69(2):101-13. Review.

PMID:
11759816
12.

Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence?

Sullivan W, Evans DG, Newman WG, Ramsden SC, Scheffer H, Payne K.

Genet Test Mol Biomarkers. 2012 Jun;16(6):580-91. doi: 10.1089/gtmb.2011.0236. Epub 2012 Feb 7. Review.

PMID:
22313048
13.

Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.

Basu NN, Barr L, Ross GL, Evans DG.

Int J Surg Oncol. 2015;2015:901046. doi: 10.1155/2015/901046. Epub 2015 Jan 27. Review.

Items per page

Supplemental Content

Write to the Help Desk